2024
Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021
Kwon J, Pelletiers W, Peña J, van Duin D, Ledbetter L, Baum K, Ruffin F, Knisely J, Bizzell E, Fowler V, Chambers H, Pettigrew M. Participant Diversity in United States Randomized Controlled Trials of Antibacterials for Staphylococcus aureus Infections, 2000–2021. Clinical Infectious Diseases 2024, 79: 141-147. PMID: 38306502, PMCID: PMC11259209, DOI: 10.1093/cid/ciae049.Peer-Reviewed Original ResearchMethicillin-resistant S. aureusRandomized Controlled TrialsPhase 2/3 trialsPhase 4 trialIncidence of methicillin-resistant S. aureusTreat Staphylococcus aureus infectionsStaphylococcus aureus infectionStandard of carePercentage of study participantsIncidence ratiosClinical trialsEthnicity of participantsControlled TrialsStandardized reporting methodsBlack participantsStudy sizeInfectionDisease populationTrialsStudy participantsAntibacterial agentsIncreased recruitmentIndustry sponsorshipEthnicity dataSex
2020
175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP)
Williams D, Creech C, Walter E, Martin J, Gerber J, Newland J, Howard L, Hofto M, Staat M, Oler R, Conrad T, Tuyishimire B, Pettigrew M, Fowler V, Chambers H, Zaoutis T, Evans S, Huskins W. 175. Randomized Double-blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). Open Forum Infectious Diseases 2020, 7: s216-s216. PMCID: PMC7776421, DOI: 10.1093/ofid/ofaa439.485.Peer-Reviewed Original ResearchShort-course therapyCourse therapyAntibiotic exposureClinical improvementOutpatient therapyAdverse effectsDouble-blind Controlled TrialPlacebo-controlled superiority trialDays of antibioticsInitial clinical improvementShort antibiotic exposureShorter antibiotic coursesCommunity-acquired pneumoniaStart of therapyCAP treatmentChildren ages 6Antibiotic coursesInitial therapyAcquired PneumoniaBaseline characteristicsClinical responseSecondary outcomesStandard therapyControlled TrialsPrimary outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply